Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis, Inc.

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Codexis, with a price target of $11.00. According ...

Cantor Fitzgerald Keeps Their Buy Rating on Codexis (CDXS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on C4 Therapeutics (CCCC), Codexis (CDXS) and LENZ Therapeutics (LEN...

Analysts Conflicted on These Healthcare Names: C4 Therapeutics (CCCC), Codexis (CDXS) and LENZ Therapeutics (LENZ)

Codexis ( ($CDXS) ) has shared an announcement. On July 23, 2026, Codexis, Inc. entered into an underwriting agreement with Piper Sandler & Co. and...

Codexis completes public equity offering to bolster liquidity

Codexis ( ($CDXS) ) has shared an update. Codexis disclosed a brief regulatory update indicating that the information previously reported under Ite...

Codexis Issues Brief Regulatory Filing Update Notice

In a report released on July 17, Matt Hewitt from Craig-Hallum maintained a Buy rating on Codexis. The company’s shares closed last Friday at $2.24...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CDXS	$1.56	0.00%	1.36M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CDXS	$1.56	0%	1.36M
3
4
5
6

CDXS

Get Codexis, Inc. Data in Excel

Get Codexis, Inc. Data in Excel